Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK10 | O94804 | 3/20 | 0.43 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.40 |
| ▸ | ERN1 | O75460 | 6/20 | 0.38 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958892 | 0.82 | ERN1 (0.48) | STK10SLKERN1ALDH1A1 | |
| SCHEMBL4958315 | 0.78 | ALDH1A1 (0.43) | ERN1ALDH1A1 | |
| SCHEMBL31551012 | 0.76 | ERN1 (0.50) | STK10SLKERN1 | |
| SCHEMBL4958641 | 0.75 | RXRA (0.38) | ERN1ALDH1A1 | |
| SCHEMBL4961194 | 0.72 | HSD11B1 (0.45) | STK10SLKHSD11B1TRPA1TRPM8 | |
| SCHEMBL31136877 | 0.72 | ERN1 (0.41) | ERN1 | |
| SCHEMBL1125310 | 0.71 | ERN1 (0.57) | ERN1NFKB1 | |
| SCHEMBL4846671 | 0.71 | MEN1 (0.46) | HSD11B1NFKB1ALDH1A1HPGD | |
| SCHEMBL30843799 | 0.71 | ERN1 (0.57) | ERN1NFKB1 | |
| SCHEMBL13290025 | 0.71 | STK10 (0.47) | STK10SLKHSD11B1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | STK10 3503/4885SLK 2688/4885HSD11B1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.